Seqalis

Seqalis is a private, revenue-generating service provider in the diagnostics and genomics sector, operating a specialized laboratory in Belgium. It serves as a contract research organization (CRO) and testing partner for biotech and pharmaceutical companies, offering a suite of technical services including sequencing, histopathology, and custom assay development. The company is actively involved in high-profile research collaborations, such as the AURORA breast cancer project, indicating its role in supporting clinical and translational research. Its business model is focused on providing fee-for-service laboratory analyses and scientific advisory, rather than developing its own therapeutic products.

Integrated laboratory service platform specializing in Molecular Biology (DNA/RNA Sequencing, PCR, T Cell Repertoire Sequencing), Cytogenomics, and Anatomical Pathology (Histopathology), supported by biobanking and scientific advisory.

Operates in a crowded market competing against large global CROs (e.g., LabCorp, IQVIA), specialized genomic service providers (e.g., Eurofins, Genewiz), and academic core facilities. Differentiates through a focus on high-touch scientific collaboration, niche expertise in T cell repertoire sequencing, and its position within the European biotech hub.